BRAFV600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma.

BRAFV600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. Oncotarget. 2019 Dec 03;10(64):6870-6878 Authors: Chui MH, Kjaer SK, Frederiksen K, Hannibal CG, Wang TL, Vang R, Shih IM Abstract Ovarian serous borderline tumor (SBT) is a known precursor of low-grade serous carcinoma. While most SBTs are cured surgically, some progress to carcinoma and a risk predictor for malignant relapse is needed to ensure vigilant follow-up and additional treatment. Activating mutations in KRAS or BRAF are present in around 60% of SBTs, but their relative impact on progression is unclear. We performed mutational analysis of KRAS and BRAF on 201 SBTs identified from a longitudinal cohort of SBTs after centralized pathology review. Compared to wildtype and KRAS-mutated SBTs, BRAF-mutated group of SBTs were less likely to exhibit micropapillary variant histology (p
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Related Links:

In conclusion, some women with SBTs can subsequently develop serous carcinoma, occasionally over 10 years later. Most subsequent carcinomas are low grade, but a small subset can be high grade. The type of gene mutation in SBT correlates with various histologic features. While most cases of serous carcinoma developing after a diagnosis of SBT probably represent tumor progression, a minority are independent primary tumors, presumably arising from endosalpingiosis.
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
Focal micropapillary features in invasive urothelial carcinoma is sometimes difficult to distinguish from retraction artifact morphologically. Cell polarity reversal has been demonstrated in micropapillary tumors by epithelial membrane antigen (EMA) immunostaining. We have previously described the use of E-cadherin as a cell polarity marker in ovarian micropapillary serous borderline tumors. The aim of this study was to evaluate the utility of immunohistochemistry for EMA and E-cadherin in differentiating micropapillary urothelial carcinoma from retraction artifact. We identified 29 invasive urothelial carcinomas with micr...
Source: Applied Immunohistochemistry and Molecular Morphology - Category: Chemistry Tags: Online Articles: Research Articles Source Type: research
Ovarian serous borderline tumors (SBTs) have been the subject of considerable controversy, particularly with regard to terminology and behavior. It has been proposed that they constitute a heterogenous group of tumors composed, for the most part, of typical SBTs that are benign and designated “atypical proliferative serous tumor (APST)” and a small subset of SBTs with micropapillary architecture that have a poor outcome and are designated “noninvasive low-grade serous carcinoma (niLGSC)”. It also has been argued that the difference in behavior between the 2 groups is not due to the subtype of the pr...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
c R Abstract Borderline tumors (BOT) of the ovary account for 10% to 20% of ovarian neoplasms. Like ovarian cancer, BOT encompass several different histological subtypes (serous, mucinous, endometrioid, clear cell, transitional cell and mixed) with serous (SBOT) and mucinous (MBOT) the most common. Current hypotheses suggest low-grade serous carcinoma may develop in a stepwise fashion from SBOT whereas the majority of high grade serous carcinomas develop rapidly presumably from inclusion cysts or ovarian surface epithelium. The pathogenesis of mucinous ovarian tumors is still puzzling. Molecular markers could help...
Source: Pathology Oncology Research - Category: Pathology Authors: Tags: Pathol Oncol Res Source Type: research
Approximately 3000 American women are diagnosed with borderline ovarian tumours annually. Borderline tumours present similar to other types of adnexal masses. Prognostic factors include FIGO stage, presence of peritoneal implants, micropapillary pattern (for serous histology), microinvasion, and intraepithelial carcinoma (for mucinous histology). Approximately 65-70% of serous tumours and 90% of mucinous tumours are stage I, and 30% and 10%, respectively, are associated with extra-ovarian spread.
Source: Best Practice and Research. Clinical Obstetrics and Gynaecology - Category: OBGYN Authors: Source Type: research
Conclusions: The risk of recurrence is higher after FPS compared with RS; however, no influence on OS was observed. This was because most of the patients relapsed as BOT. Fertility preservation is justified in young patients with serous borderline tumors.
Source: International Journal of Gynecological Cancer - Category: Cancer & Oncology Tags: Ovarian Cancer Source Type: research
Low-grade serous carcinoma (LGSC) is an uncommon but distinct histologic subtype of ovarian carcinoma. Although the histologic features and natural history of LGSC have been described in the literature, there is no robust correlative study that has specifically addressed histologic features in correlation with clinical follow-up. To refine the criteria for invasion patterns of LGSC and determine additional clinically pertinent morphologic features of LGSC predisposing to a more aggressive clinical course, the clinicopathologic features of 52 LGSCs were evaluated and compared with those of a large series of serous borderlin...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
We present the case of a 47-year-old woman who presented with pelvic discomfort. Pathology showed a serous borderline tumor with multifocal microinvasion, noninvasive tumor implants, and lymph node involvement. Serous borderline tumors are ovarian neoplasms that display branching papillary growth, epithelial stratification, and mild cytologic atypia without destructive stromal invasion. They frequently have mutations in either KRAS or BRAF and are considered to be precursors to low-grade serous carcinoma. Serous borderline tumor nomenclature, natural history, and the significance of histopathologic features such as microin...
Source: Pathology Case Reviews - Category: Pathology Tags: Case Reviews Source Type: research
This article is protected by copyright. All rights reserved.
Source: Histopathology - Category: Pathology Authors: Tags: Correspondence Source Type: research
This article is protected by copyright. All rights reserved.
Source: Histopathology - Category: Pathology Authors: Tags: Correspondence Source Type: research
More News: Borderline Serous Tumor | Borderline Tumor | Cancer & Oncology | Carcinoma | Micropapillary Carcinoma | Ovarian Cancer | Ovaries | Pathology | Serous Carcinoma | Study